The results of the Phase 2a clinical trial of the nasal spray COVID-19 immunotherapy drug AD17002 were published in the journal Human Vaccines & Immunotherapeutics. The study demonstrates that AD17002 shows good safety and tolerability in patients wit
The results of the Phase 2a clinical trial of the nasal spray COVID-19 immunotherapy drug AD17002 were published in the journal Human Vaccines & Immunotherapeutics. The study demonstrates that AD17002 shows good safety and tolerability in patients wit
